Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Amortization - Intangibles (2018 - 2025)

Rocket Pharmaceuticals' Amortization - Intangibles history spans 8 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Amortization - Intangibles fell 1.23% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $7.3 million, down 9.67%, while the annual FY2025 figure was $7.3 million, 9.67% down from the prior year.
  • Amortization - Intangibles for Q4 2025 was $1.2 million at Rocket Pharmaceuticals, down from $1.7 million in the prior quarter.
  • Across five years, Amortization - Intangibles topped out at $3.3 million in Q4 2023 and bottomed at -$801000.0 in Q4 2021.
  • The 5-year median for Amortization - Intangibles is $1.5 million (2024), against an average of $1.2 million.
  • The largest annual shift saw Amortization - Intangibles plummeted 1130.65% in 2021 before it soared 1560.9% in 2023.
  • A 5-year view of Amortization - Intangibles shows it stood at -$801000.0 in 2021, then skyrocketed by 234.96% to $1.1 million in 2022, then soared by 202.96% to $3.3 million in 2023, then tumbled by 62.66% to $1.2 million in 2024, then dropped by 1.23% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Amortization - Intangibles are $1.2 million (Q4 2025), $1.7 million (Q3 2025), and $2.2 million (Q2 2025).